Overview

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International Headache Society [IHS] Grade 1) of MM compared with patients' current treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Endo Pharmaceuticals
Treatments:
Frovatriptan